Nephrol Dial Transplant (2002) 17: 637-644
© 2002 European Renal Association-European Dialysis and Transplant Association
Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients
My
liwiec
Department of Nephrology and Internal Medicine, Medical Academy, Biaystok, Poland
Background. Increased serum hepatocyte growth factor (HGF) level is a part of the counter-system against tissue damage and predicts mortality in maintenance haemodialysis (HD) patients. We studied which of the common co-morbid and clinical conditions, and surrogates of metabolic disorders or specific organ damage determine HGF levels in these subjects.
Methods. In 86 patients, pre-dialysis serum HGF, soluble endothelial markers—such as thrombomodulin (TM), von Willebrand factor and plasminogen activator inhibitor-1—and hepatitis B and C markers were measured by ELISAs. Inflammatory reactants such as C-reactive protein (CRP), 
1-antitrypsin, 1 acid-glycoprotein, and immunoglobulin M and G were assayed by nephelometry, and lipoprotein(a) was determined by ELISA. Cardiovascular disease (CVD) was identified on a clinical basis.
Results. Serum HGF was directly associated with the presence of viral hepatitis, alanine aminotransferase and TM levels, time on HD, the presence of CVD, CRP and 1-antitrypsin levels, use of unfractionated heparin (UFH) (vs enoxaparin) during HD, dose of UFH, use of recombinant erythropoietin (rHuEpo) treatment, and Kt/V. In 36 patients not treated with rHuEpo, HGF directly correlated with haemoglobin, but not with endogenous Epo levels. There was no association between HGF and the other endothelial and inflammatory markers, gender, age, smoking, cause of renal failure, body mass index, normalized protein catabolic rate, dialysate buffers, dialysers, blood pressure, antihypertensive treatment, leukocyte and platelet counts, albumin, fibrinogen, lipoprotein(a), markers of iron and calcium–phosphorus metabolism, or metabolic acidosis. Positive viral hepatitis markers, prevalent CVD and rHuEpo treatment (in descending order of significance) were independent predictors of high HGF level. In another 20 HD patients, a 4-week course of rHuEpo treatment resulted in a significant 17% increase in circulating HGF levels.
Conclusion. Serum HGF levels in HD patients are determined by inflammatory conditions such as viral hepatitis and CVD, increase in response to rHuEpo treatment, and may be influenced by type and dose of heparin used during HD procedures.
Keywords: cardiovascular disease; erythropoietin; haemodialysis; heparin; hepatocyte growth factor; viral hepatitis
Correspondence and offprint requests to: Dr Jacek Borawski, Department of Nephrology and Internal Medicine, Medical Academy, 14 Zurawia Street, PL-15-540 Biaystok, Poland. Email: jborawsk{at}polbox.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Borawski, B. Naumnik, and M. Mysliwiec Striking increase in circulating hepatocyte growth factor during enoxaparin-anticoagulated haemodialysis Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1680 - 1682. [Full Text] [PDF]
|
|
|
|
|
|
J. Borawski, B. Naumnik, and M. Mysliwiec Striking increase in circulating hepatocyte growth factor during enoxaparin-anticoagulated haemodialysis Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1680 - 1682. [Full Text]
|
|
|
|
 |
|
 J. Borawski, B. Naumnik, and M. My'liwiec Hepatocyte Growth Factor: A Possible Mediator of Heparin-induced Osteoporosis? Clinical and Applied Thrombosis/Hemostasis, April 1, 2003; 9(2): 171 - 172. [PDF]
|
|